Cargando…

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease

INTRODUCTION: Empagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, is approved in the USA to reduce risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus (T2DM) and established CV disease, based on EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reifsnider, Odette S, Kansal, Anuraag R, Gandhi, Pranav K, Cragin, Lael, Brand, Sarah B, Pfarr, Egon, Fahrbach, Kyle, Ustyugova, Anastasia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098979/ https://www.ncbi.nlm.nih.gov/pubmed/33941549 http://dx.doi.org/10.1136/bmjdrc-2020-001313

Ejemplares similares

Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure
por: Reifsnider, Odette S., et al.
Publicado: (2020)

Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States
por: Reifsnider, Odette, et al.
Publicado: (2020)

Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia
por: Kansal, Anuraag R., et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
por: Ramos, Mafalda, et al.
Publicado: (2019)

Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA‐REG OUTCOME trial
por: Kansal, A., et al.
Publicado: (2019)

Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
por: Balijepalli, Chakrapani, et al.
Publicado: (2018)

Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study
por: Kudo, Akihiro, et al.
Publicado: (2023)

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
por: Ramos, Mafalda, et al.
Publicado: (2021)

Restoring Insulin Secretion (RISE): Design of Studies of β-Cell Preservation in Prediabetes and Early Type 2 Diabetes Across the Life Span
Publicado: (2014)

Enhancement of Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes
por: Novak, Vera, et al.
Publicado: (2014)

Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose
por: Sherr, Jennifer L., et al.
Publicado: (2014)

Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment
por: Orban, Tihamer, et al.
Publicado: (2014)

Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges
por: Ghazi, Tara, et al.
Publicado: (2014)

Overnight Glucose Control With an Automated, Unified Safety System in Children and Adolescents With Type 1 Diabetes at Diabetes Camp
por: Ly, Trang T., et al.
Publicado: (2014)

Performance of the Medtronic Sentrino continuous glucose management (CGM) system in the cardiac intensive care unit
por: Kosiborod, Mikhail, et al.
Publicado: (2014)

B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results
por: Pescovitz, Mark D., et al.
Publicado: (2014)

Internet-delivered cognitive behaviour therapy for depression in people with diabetes: study protocol for a randomised controlled trial
por: Robins, Lisa, et al.
Publicado: (2015)

Feasibility of overnight closed-loop therapy in young children with type 1 diabetes aged 3–6 years: comparison between diluted and standard insulin strength
por: Elleri, Daniela, et al.
Publicado: (2014)

Vitamin D for the treatment of painful diabetic neuropathy
por: Basit, Abdul, et al.
Publicado: (2016)

Preexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserving Residual β-Cell Function in Recent-Onset Type 1 Diabetes
por: Demeester, Simke, et al.
Publicado: (2015)

Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study
por: Skyler, Jay S., et al.
Publicado: (2015)

Inhaled Formoterol Diminishes Insulin-Induced Hypoglycemia in Type 1 Diabetes
por: Belfort-DeAguiar, Renata D., et al.
Publicado: (2015)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

Rationale and Design of the Vitamin D and Type 2 Diabetes (D2d) Study: A Diabetes Prevention Trial
por: Pittas, Anastassios G., et al.
Publicado: (2014)

Metabolic Effects of Exercise Training Among Fitness-Nonresponsive Patients With Type 2 Diabetes: The HART-D Study
por: Pandey, Ambarish, et al.
Publicado: (2015)

Effect of Repeated Glucagon Doses on Hepatic Glycogen in Type 1 Diabetes: Implications for a Bihormonal Closed-Loop System
por: Castle, Jessica R., et al.
Publicado: (2015)

Impact of symptomatic upper respiratory tract infections on insulin absorption and action of Technosphere inhaled insulin
por: Levin, Philip A, et al.
Publicado: (2016)

Improved diabetes medication convenience and satisfaction in persons with type 2 diabetes after switching to insulin glargine 300 U/mL: results of the observational OPTIN-D study
por: Wieringa, Thomas H, et al.
Publicado: (2018)

Performance of the FreeStyle Libre Flash glucose monitoring system in patients with type 1 and 2 diabetes mellitus
por: Fokkert, M J, et al.
Publicado: (2017)

Identification of Unique Antigenic Determinants in the Amino Terminus of IA-2 (ICA512) in Childhood and Adult Autoimmune Diabetes: New Biomarker Development
por: Acevedo-Calado, Maria, et al.
Publicado: (2017)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
por: Sokolov, Victor, et al.
Publicado: (2020)

Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus
por: Nakagaito, Masaki, et al.
Publicado: (2019)

Cost‐effectiveness of second‐line empagliflozin versus liraglutide for type 2 diabetes in the United States
por: Reifsnider, Odette S., et al.
Publicado: (2022)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

Sex-dependent effects of canagliflozin and dapagliflozin on hemostasis in normoglycemic and hyperglycemic mice
por: Marcińczyk, Natalia, et al.
Publicado: (2023)

Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study
por: Shima, Kosuke Robert, et al.
Publicado: (2018)

Impact of Ramadan fasting on glucose levels in women with gestational diabetes mellitus treated with diet alone or diet plus metformin: a continuous glucose monitoring study
por: Afandi, Bachar O, et al.
Publicado: (2017)

Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study
por: Inagaki, Nobuya, et al.
Publicado: (2017)

Validity and reliability of anti-diabetic medication adherence scale among patients with diabetes in Baghdad, Iraq: a pilot study
por: Mikhael, Ehab Mudher, et al.
Publicado: (2019)

Unilateral remote temperature monitoring to predict future ulceration for the diabetic foot in remission
por: Lavery, Lawrence A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b1bl6kmt4snhemjbciseus4n4n